Core Viewpoint - The stock of He Yu-B (02256) has risen over 6%, reaching a new high of 18 HKD, driven by recent share buybacks and positive financial performance [1] Group 1: Stock Performance - He Yu-B's stock price increased by 5.56%, trading at 17.84 HKD with a transaction volume of 34.38 million HKD [1] - The company has conducted share buybacks, repurchasing 200,000 shares on August 27 and another 100,000 shares on August 28, totaling 9.545 million shares repurchased for 75.3 million HKD as of June 30, 2025 [1] Group 2: Shareholding Changes - Allianz SE increased its stake in He Yu-B from 4.81% to 5.10% as of August 15 [1] Group 3: Financial Performance - In the first half of the year, the company reported revenue of 657 million RMB, a year-on-year increase of 20%, and a net profit of 328 million RMB, up 59% [1] - The company holds cash reserves of 2.3 billion RMB, providing a solid foundation for future research and operations [1] - Growth is primarily attributed to the core product, ABKS021 (Pimiatin), in collaboration with Merck, which exercised its global commercialization option in the first half of 2025, paying an exercise fee of 85 million USD [1] Group 4: Future Outlook - The company is expected to benefit from the global approval and commercialization of Pimiatin, with ongoing milestone payments and sales sharing [1] - The steady progress in the registration and listing of Pimiatin, along with healthy financial performance, indicates sustainability in the medium term [1]
和誉-B涨超6%再创新高 公司连续回购并获外资股东增持 稳步推进匹米替尼注册上市